FTC Urged To Investigate AbbVie’s IP Strategy On Humira

US Representatives Suggest Biosimilar Adalimumab Competition Delayed From 2017 To 2023

Hourglass Delay Stop Time
The FTC has been asked to investigate AbbVie over delays to Humira biosimilars • Source: Alamy

More from Biosimilars

More from Products